Printed from Voxsanity (voxsanity.com.au) — NCT07202897 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
Back to Cardiomyopathy
Phase 3 Cardiomyopathy Trial, Recruiting
NCT07202897
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are between 40 and 80 years old
- You weigh between 50 and 120 kg (approximately 110 to 265 lbs)
- Your heart is beating in a normal, regular rhythm (called "sinus rhythm")
- You have previously been diagnosed with a specific heart condition called "primary" hypertrophic cardiomyopathy (a condition where the heart muscle is thickened for no secondary reason)
- A specific heart scan measurement related to how the upper left chamber of your heart functions shows a result of 20% or below (confirmed by a specialist lab)
- You are willing and able to sign a consent form agreeing to take part
- If you are a woman who could become pregnant, you agree to use highly effective contraception starting at least 14 days before the study begins, throughout the study, and for at least 4 weeks after your last dose of study medication
Who may not be able to join:
- Your hypertrophic cardiomyopathy is caused by another condition, such as a narrowed heart valve, high blood pressure, or a protein build-up disease (called amyloidosis), among others
- You currently show signs of heart failure
- You are currently hospitalised
- Your blood pressure is not well controlled
- Your kidneys are not working well enough (confirmed with a specific kidney function test — confirm with trial site)
- You have serious liver disease or advanced liver scarring (cirrhosis)
- You have taken any blood-thinning medication in the 15 days before enrolling
- You have had heart surgery in the 30 days before enrolling
- You have a documented irregular heart rhythm in the upper chambers of your heart (atrial arrhythmia)
- You have had a major bleeding episode in the 90 days before enrolling
- You need to take two blood-thinning/anti-clotting medications at the same time (such as high-dose aspirin together with certain other specific medications — confirm with trial site)
- You are unable to have a brain MRI scan for any reason
- You have a known allergy or other medical reason preventing you from taking the study drug, Rivaroxaban
- You have had a stroke or bleeding in the brain in the 30 days before enrolling
- You currently have an active infection of the heart valves (endocarditis)
- You are taking certain medications that strongly interact with the study drug (confirm with trial site)
- You have active cancer, or your life expectancy is less than 3 years
- You are unlikely to follow the study requirements as instructed
- You are already taking part in another clinical trial that involves a treatment or intervention
- You are pregnant, breastfeeding, planning to become pregnant during the study, are a minor, or are legally under guardianship or protective supervision, or are deprived of your liberty
- You are not covered by a social security or health insurance scheme (this requirement may be specific to the country running the trial — confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.
Contact this trial
Principal Investigator: Donal Erwan, Rennes University Hospital
Phone: 02 99 28 25 55
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Status
Recruiting
Phase
Phase 3
Sponsor
Rennes University Hospital
Registry
ClinicalTrials.gov
Start date
7 January 2026
Est. completion
7 January 2032
Where this trial is recruiting
🇫🇷 France
Primary endpoints
all-cause death, myocardial infarction, stroke and systemic embolism
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.